A Safety Study of EPC2407, A Anti-Cancer Drug With Vascular Disrupting Activity: In Patients With Advanced Cancer
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, pharmacokinetics (PK), and pharmacodynamic effects of a
novel anti-cancer drug, EPC2407, administered to patients with advanced cancer which have not
responded to or have recurred following treatment with available therapies